EMMPRIN regulates the canonical Wnt/Β-catenin signaling pathway, a potential role in accelerating lung tumorigenesis

Oncogene

Volumn 29, Issue 29, 2010, Pages 4145-4156

  Sidhu, S S ^a   Nawroth, R ^a,b   Retz, M ^a,b   Lemjabbar Alaoui, H ^a   Dasari, V ^a   Basbaum, C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

b catenin; CD147; EMMPRIN; lung cancer; Wnt

Indexed keywords

BETA CATENIN; CD147 ANTIGEN; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIGENS, CD147; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; PHENOTYPE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77954951632     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.166     Document Type: Article

References (63)

1. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE et al. (2007). Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 13: 4407-4414.
2. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbano-wicz B, Branski P et al. (2006). Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 55: 808-818.
3. Bartscherer K, Boutros M. (2008). Regulation of Wnt protein secretion and its role in gradient formation. EMBO Rep 9: 977-982.
4. Berditchevski F, Chang S, Bodorova J, Hemler ME. (1997). Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 272: 29174-29180.
5. Betsuyaku T, Tanino M, Nagai K, Nasuhara Y, Nishimura M, Senior RM. (2003). Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid. Am J Respir Crit Care Med 168: 222-227.
6. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H et al. (1995). The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55: 434-439.
7. Bonner AE, Lemon WJ, You M. (2003). Gene expression signatures identify novel regulatory pathways during murine lung development: implications for lung tumorigenesis. J Med Genet 40: 408-417.
8. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R et al. (2004). Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 90: 224-229.
9. Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S et al. (1999). Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in broncho-pulmonary and breast lesions. J Histochem Cytochem 47: 1575-1580.
10. Coussens LM, Fingleton B, Matrisian LM. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
11. Daniel VC, Peacock CD, Watkins DN. (2006). Developmental signalling pathways in lung cancer. Respirology 11: 234-240.
12. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. (2003). EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20: 161-169.
13. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. (2005). Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci USA 102: 16245-16250.
14. Fadool JM, Linser PJ. (1996). Evidence for the formation of multimeric forms of the 5A11/HT7 antigen. Biochem Biophys Res Commun 229: 280-286.
15. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. (2005). EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87: 361-368.
16. Gagliardi M, Piddini E, Vincent JP. (2008). Endocytosis: a positive or a negative influence on Wnt signalling? Traffic 9: 1-9.
17. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. (1997). Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 272: 24-27.
18. Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L et al. (2008). Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 374: 517-521.
19. Klaus A, Birchmeier W. (2008). Wnt signalling and its impact on development and cancer. Nat Rev Cancer 8: 387-398.
20. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O et al. (2002). Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 20: 387-392.
21. Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H et al. (2005). Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 14: 1608-1612.
22. Lemjabbar H, Li D, Gallup M, Sidhu S, Drori E, Basbaum C. (2003). Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J Biol Chem 278: 26202-26207.
23. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D et al. (2010). Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene 29: 635-646.
24. Lin X. (2004). Functions of heparan sulfate proteoglycans in cell signaling during development. Development 131: 6009-6021.
25. Logan CY, Nusse R. (2004). The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20: 781-810.
26. Lowy AM, Clements WM, Bishop J, Kong L, Bonney T, Sisco K et al. (2006). beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. Cancer Res 66: 4734-4741.
27. McEntee MF, Chiu CH, Whelan J. (1999). Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis 20: 635-640.
28. Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S et al. (2007). Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9: 349-357.
29. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. (2004). WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
30. Morrisey EE. (2003). Wnt signaling and pulmonary fibrosis. Am J Pathol 162: 1393-1397.
31. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. (2006). Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56: 359-367.
32. Nawroth R, Stohr R, Hartmann A, Gschwend JE, Retz M. (2008). [EMMPRIN (CD147): a new key protein during tumor progression in bladder cancer.]. Urologe A 47: 1152-1156.
33. Overall CM, Kleifeld O. (2006). Tumour microenvironment\opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239.
34. Overall CM, Lopez-Otin C. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672.
35. Parkin DM, Bray F, Ferlay J, Pisani P. (2005). Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
36. Pasca di Magliano M, Biankin AV, Heiser PW, Cano DA, Gutierrez PJ, Deramaudt T et al. (2007). Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2: e1155.
37. Polakis P. (2007). The many ways of Wnt in cancer. Curr Opin Genet Dev 17: 45-51.
38. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S et al. (2004). Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10: 3422-3428.
39. Renno T, Wilson A, Dunkel C, Coste I, Maisnier-Patin K, Benoit de Coignac A et al. (2002). A role for CD147 in thymic development. J Immunol 168: 4946-4950.
40. Reya T, Clevers H. (2005). Wnt signalling in stem cells and cancer. Nature 434: 843-850.
41. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G et al. (2006). High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810.
42. Roth W, Wild-Bode C, Platten M, Grimmel C, Melkonyan HS, Dichgans J et al. (2000). Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 19: 4210-4220.
43. Safholm A, Tuomela J, Rosenkvist J, Dejmek J, Harkonen P, Andersson T. (2008). The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res 14: 6556-6563.
44. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. (2004). Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10: 55-63.
45. Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. (2004). The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 23: 956-963.
46. Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C et al. (2008). Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 21: 1130-1138.
47. Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM. (2003). Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 278: 11465-11470.
48. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. (2002). Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep 3: 63-68.
49. Sun J, Hemler ME. (2001). Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 61: 2276-2281.
50. Taketo MM. (2004). Shutting down Wnt signal-activated cancer. Nat Genet 36: 320-322.
51. Tang W, Chang SB, Hemler ME. (2004). Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 15: 4043-4050.
52. Tang W, Hemler ME. (2004). Caveolin-1 regulates matrix metallo-proteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem 279: 11112-11118.
53. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P et al. (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199.
54. Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H et al. (2006). Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 4: 371-377.
55. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. (2003). Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22: 7218-7221.
56. Van Scoyk M, Randall J, Sergew A, Williams LM, Tennis M, Winn RA. (2008). Wnt signaling pathway and lung disease. Transl Res 151: 175-180.
57. Wang WJ, Li QQ, Xu JD, Cao XX, Li HX, Tang F et al. (2008). Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 54: 291-301.
58. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M et al. (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1: 279-288.
59. Wiznerowicz M, Trono D. (2003). Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77: 8957-8961.
60. Yan L, Zucker S, Toole BP. (2005). Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93: 199-204.
61. Yang JM, O'Neill P, Jin W, Foty R, Medina D, Xu Z et al. (2006). Emmprin (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. J Biol Chem 281: 9719-9727.
62. Yu XL, Hu T, Du JM, Ding JP, Yang XM, Zhang J et al. (2008). Crystal structure of HAb18G/CD147: implications for immuno-globulin superfamily homophilic adhesion. J Biol Chem 283: 18056-18065.
63. Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M. (2005). Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem 280: 17013-17019.